*CAUTION, only read my post if you value contrarian insights and...

*CAUTION, only read my post if you value contrarian insights and opinions rather than pom-pom club talking points, pie-in-the-sky possible developments, fantasy share price predictions, and one-liner pot shot attacks at posters that go against the warm and comfy positive narrative.

In May 2024 I posted:
Pre-clinical results from DEP-HER2 ADC in 2015.

"We are very excited by these latest results for our targeted DEP ™ conjugates and feedback from commercial parties on this new data has been very positive indeed. Discussions are now underway with a number of pharmaceutical companies in relation to this targeted DEP conjugate …” ~ CEO

Meanwhile, almost 9 years later ….


Then in Oct 2024 I posted:
’So what the hell have Starpharma been doing with DEP-HER2 ADC ? It appears to have not only stalled but regressed! Back in a 2020 presentation it was clearly identified as being in pre-clinical phase.
Now in 2024 it is identified as being further back in research phase. (With the goal of advancing to pre-clinical.This company is withering on a vine IMO.
Compare the 2 presentations below:




In Oct 2024 I then wrote to Investor Relations regarding the slow progress and apparent regression of this program. I did receive a confidential response.

Now, in Jan 2025 we found out that Starpharma have chosen to ‘redirect the focus of our ADC program to explore other targets’. Code for termination the DEP-HER2 ADC program in my opinion.

It now makes sense. It seems the 10 year + research and early pre-clinical development of DEP-HER2 ADC had some setbacks and the company could not justify further development.

All IMHO.